GLP-1 Agonist vs. Retatrutide Explained

A GLP-1 agonist is a molecule that binds to the GLP-1 receptor and mimics that hormone's natural signaling in the body. Retatrutide isn't a simple GLP-1 agonist: it's a triple agonist, meaning it activates that same receptor plus two more, GIP and glucagon, at the same time. The difference isn't about brand or potency — it's about how many distinct receptors the molecule engages.

What a GLP-1 receptor agonist is

GLP-1 is an incretin: a hormone the gut releases after eating that acts on several organs at once, including the pancreas, the stomach, and the brain. A GLP-1 agonist is a synthetic molecule built to bind that hormone's receptor and trigger the same signaling cascade. Semaglutide is the best-studied example of this class — it activates a single receptor, GLP-1 — and that single-receptor mechanism is what was investigated in Wilding et al., NEJM 2021 (STEP 1) in adults with overweight or obesity. Semaglutide, as a molecule, has been approved by the FDA under the brand names Ozempic, for type 2 diabetes, and Wegovy, for chronic weight management.

From there, research moved toward molecules that activate more than one receptor in a single peptide. Tirzepatide, a dual agonist of GLP-1 and GIP, was investigated in Jastreboff et al., NEJM 2022 (SURMOUNT-1); that molecule has since been approved by the FDA under the brand names Mounjaro and Zepbound. The next step up from dual agonism is triple agonism, and that's where retatrutide sits.

GLP-1 agonist vs. retatrutide, side by side

Why retatrutide adds GIP and glucagon

The GIP receptor (glucose-dependent insulinotropic polypeptide) is another gut-derived incretin, and the glucagon receptor regulates hepatic glucose release and energy expenditure. Adding activation of those two receptors to GLP-1, in the same molecule, is what the literature calls triple agonism, and it's the mechanism that sets retatrutide apart from a conventional GLP-1 agonist like semaglutide or from the dual agonist tirzepatide.

That molecular design was tested in the phase 2 trial led by Jastreboff et al. (NEJM, 2023) in adults with obesity. The study measured clinical endpoints in its own participants, including body weight, over the trial period. That is a statement about what the trial's participants experienced during that research, not about what would happen to someone using the material outside that context, and this is not a promise PeptoClinic makes about any product it supplies.

What's approved today, and what isn't

Semaglutide and tirzepatide, as molecules, are approved drugs in the United States — but under specific brand names, manufactured by specific companies, in specific formulations. The vial PeptoClinic supplies, whichever compound it contains, is not Ozempic, not Wegovy, not Mounjaro, and not Zepbound, and carries no FDA approval of its own.

Retatrutide has no approval anywhere, in any form. It is currently in phase 3 clinical development, according to the trial published in 2026 by Jastreboff et al. in NEJM. Being in phase 3 means retatrutide has already cleared earlier phases of preliminary safety and efficacy testing; it does not mean the molecule has been approved for medical use.

This distinction matters because the question behind this post — what a GLP-1 agonist is and how retatrutide differs from one — often gets tangled with a different question: whether either molecule "can already be bought as a drug." The honest answer is that semaglutide and tirzepatide can, under the brand names above, but PeptoClinic's material is not those drug products. Retatrutide can't, under any brand, because it hasn't finished the approval process.

From phase 2 to phase 3: what changed

The 2023 trial was phase 2: a smaller-scale study meant to explore dosing and safety in a limited group of participants. The work published in 2026 by Jastreboff et al. in NEJM is phase 3, the stage where a clinical trial runs on a larger population and is the step before any eventual approval submission to the FDA. That doesn't mean retatrutide is approved — it means it cleared the previous phase and is being evaluated in the next one, and that evaluation is not finished.

Checking a lab report before comparing batches

Two molecules with different mechanisms — a single agonist versus a triple one — can also carry very different purity reports between suppliers. Before comparing a GLP-1 agonist with a triagonist like retatrutide, it's worth checking first whether the supplier publishes the laboratory report for that specific batch, with the method used and the result obtained. That's the only way to know whether the material that arrives is the one the report describes, and it's the standard PeptoClinic documents on its quality page.

If the interest is in a dual-agonist molecule instead of a triple one, tirzepatide follows the two-receptor mechanism, GLP-1 and GIP, investigated in SURMOUNT-1. If the interest is in a different kind of combination, amylin plus GLP-1, that mechanism belongs to CagriSema, a molecule distinct from retatrutide even though the two are sometimes mentioned together as part of the same generation of obesity research.